99 related articles for article (PubMed ID: 23765188)
1. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Chow VA; Rajendran JG; Fisher DR; Appelbaum FR; Cassaday RD; Martin PS; Holmberg LA; Gooley TA; Stevenson PA; Pagel JM; Green DJ; Press OW; Gopal AK
Am J Hematol; 2020 Jul; 95(7):775-783. PubMed ID: 32243637
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Puvvada SD; Guillén-Rodríguez JM; Yan J; Inclán L; Heard K; Rivera XI; Anwer F; Mahadevan D; Schatz JH; Persky DO
Oncology; 2018; 94(5):274-280. PubMed ID: 29471300
[TBL] [Abstract][Full Text] [Related]
4. A Deeper Depth of Response After Salvage Therapy Improves Outcomes of Autologous Stem Cell Transplantation in Relapsed Lymphoma and the Feasibility of Non-controlled Rate Freezing of Peripheral Blood Stem Cells.
Rab SU; Ali M; Mahar UR; Ahsan B; Ahmad U; Tariq Mahmood M; Siddiqui N; Bokhari SW
Cureus; 2024 Mar; 16(3):e56851. PubMed ID: 38659569
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Ikoma Y; Nakamura N; Kitagawa J; Miwa T; Takada E; Matsumoto T; Shibata Y; Nakamura H; Kanemura N; Kasahara S; Hara T; Sawada M; Tsurumi H; Shimizu M
Hematol Oncol; 2024 Jan; 42(1):e3236. PubMed ID: 37932900
[TBL] [Abstract][Full Text] [Related]
6. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
7. Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.
Calais PJ; Turner JH
World J Nucl Med; 2012 Sep; 11(3):110-6. PubMed ID: 23372448
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy in mantle cell lymphoma.
Skarbnik AP; Smith MR
Best Pract Res Clin Haematol; 2012 Jun; 25(2):201-10. PubMed ID: 22687456
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy in younger patients with advanced aggressive B-cell lymphoma-long-term results from the phase 3 R-MegaCHOEP trial.
Oertel M; Ziepert M; Frontzek F; Nacke N; Altmann B; Nickelsen M; Glass B; Poeschel V; Ruebe C; Lenz G; Schmitz N; Eich HT
Leukemia; 2024 May; 38(5):1099-1106. PubMed ID: 38538861
[TBL] [Abstract][Full Text] [Related]
10. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
11. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
Press OW
J Clin Oncol; 2008 Nov; 26(32):5147-50. PubMed ID: 18854559
[No Abstract] [Full Text] [Related]
12. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.
Azinovic I; DeNardo GL; Lamborn KR; Mirick G; Goldstein D; Bradt BM; DeNardo SJ
Cancer Immunol Immunother; 2006 Dec; 55(12):1451-8. PubMed ID: 16496145
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials.
Rondon A; Rouanet J; Degoul F
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771732
[TBL] [Abstract][Full Text] [Related]
14.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
15. Radioimmunotherapy-based conditioning regimen prior to autologous stem cell transplantation in non-Hodgkin lymphoma.
Eskian M; Khorasanizadeh M; Isidori A; Rezaei N
Int J Hematol Oncol; 2018 Mar; 7(1):IJH01. PubMed ID: 30302233
[TBL] [Abstract][Full Text] [Related]
16. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
17. Trial Watch-Immunostimulation with cytokines in cancer therapy.
Vacchelli E; Aranda F; Bloy N; Buqué A; Cremer I; Eggermont A; Fridman WH; Fucikova J; Galon J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Feb; 5(2):e1115942. PubMed ID: 27057468
[TBL] [Abstract][Full Text] [Related]
18. Trial Watch: Radioimmunotherapy for oncological indications.
Bloy N; Pol J; Manic G; Vitale I; Eggermont A; Galon J; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014 Oct; 3(9):e954929. PubMed ID: 25941606
[TBL] [Abstract][Full Text] [Related]
19. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
